References
- Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma; updated 2017 [cited 2017 Jun 5]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
- Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005533.
- Guidelines for the diagnosis and management of asthma – expert panel report 3. Bethesda (MD): National Institutes of Health (NIH), US Department of Health and Human Services; 2007. ( NIH publication; no. 07–4051.)
- Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med. 2004;170;836–844. doi:10.1164/rccm.200401-033OC. PMID: 15256389
- Seretide 100, 250, 500 Accuhaler. Summary of product characteristics [Internet]. GlaxoSmithKline [cited 2017 Jun 5]. Available from: https://www.medicines.org.uk/emc/medicine/2317
- ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder), for oral inhalation. Prescribing information [Internet]. GlaxoSmithKline; updated 2017 Feb [cited 2017 Jun 5]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Advair_Diskus/pdf/ADVAIR-DISKUS-PI-MG-IFU.PDF
- Flutiform 50 mcg/5 mcg, 125 mcg/5 mcg and 250 mcg/10 mcg per actuation pressurised inhalation, suspension. Summary of product characteristics [Internet]. Napp Pharmaceuticals Ltd [cited 2017 Jun 5]. Available from: https://www.medicines.org.uk/emc/medicine/26954
- Fostair 100/6 micrograms per actuation pressurised inhalation solution. Summary of product characteristics [Internet]. Chiesi Ltd [cited 2017 Jun 5]. Available from: https://www.medicines.org.uk/emc/medicine/21006
- Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder. Summary of product characteristics [Internet]. AstraZeneca [cited 2017 Jun 5]. Available from: https://www.medicines.org.uk/emc/medicine/4821
- SYMBICORT 80/4.5 (budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg); SYMBICORT 160/4.5 (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg) Inhalation Aerosol FOR ORAL INHALATION. Prescribing information [Internet]. AstraZeneca; updated 2010 Jun [cited 2017 Jun 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021929s021lbl.pdf
- DULERA (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg; 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol fumarate dihydrate 5 mcg) Inhalation Aerosol. Prescribing information [Internet]. Merck; updated 2011 Jul [cited 2017 Jun 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022518s002s004lbl.pdf
- Relvar Ellipta. Summary of product characteristics [Internet]. GlaxoSmithKline [cited 2017 Jun 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002673/WC500157633.pdf
- BREO ELLIPTA 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder), for oral inhalation; fluticasone furoate 200 mcg and vilanterol 25 mcg inhalation powder), for oral inhalation. Prescribing information [Internet]. GlaxoSmithKline; updated 2016 Jul [cited 2017 Jun 5]. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-MG.PDF
- Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1. doi:10.1186/1471-2466-10-1. PMID: 20051135
- Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment [discussion 52]. Drugs. 1999;58(Suppl 4):25–33. doi:10.2165/00003495-199958004-00004. PMID: 10711856
- Svedsater H, Stynes G, Wex J, Frith L, Leather D, Castelnuovo E, Detry M, Berry S. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma-mixed treatment comparisons of clinical efficacy. Asthma Res Pract. 2016;2:4. doi:10.1186/s40733-015-0016-0. PMID: 27965772
- Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, Jacques L, Busse WW. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144:1222–1229. doi:10.1378/chest.13-0178. PMID: 23846316
- Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpiña M, Guastalla D, Casula D, Patel S, Chanez P. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination. Pulm Pharmacol Ther. 2013;26:555–561. doi:10.1016/j.pupt.2013.01.011. PMID: 23524015
- Adachi M, Goldfrad C, Jacques L, Nishimura Y. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial. Respir Med. 2016;120:78–86. doi:10.1016/j.rmed.2016.09.018. PMID: 27817819
- Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–1343. doi:10.1183/09031936.00080312. PMID: 22743675
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65. doi:10.1016/j.jaci.2003.09.008. PMID: 14713908
- Juniper EF, Svensson K, Mörk AC, Ståhl E. Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health Qual Life Outcomes. 2005;3:58. doi:10.1186/1477-7525-3-58. PMID: 16168050
- Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–87. doi:10.1016/0895-4356(94)90036-1. PMID: 8283197
- Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care [Internet]. GlaxoSmithKline; updated 2017 May 5 [cited 2017 Jun 5]. Available from: http://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compared-with-their-usual-care/